Does inhibition of the CXCL1-CXCR2 axis prevent angiotensin II-induced cardiac hypertrophy and remodelling?
Inhibition of the CXCL1-CXCR2 axis may represent a novel therapeutic target for treating hypertensive heart disease by reducing monocyte infiltration and cardiac remodeling.
Angiotensin II-induced infiltration of monocytes in the heart is largely mediated by CXCL1-CXCR2 signalling which initiates and aggravates cardiac remodelling. Inhibition of CXCL1 and/or CXCR2 may represent new therapeutic targets for treating hypertensive heart diseases.
Wang et al. (Fri,) studied this question.